Selective peroxisome proliferator-activated receptor-α modulator improves hypertriglyceridemia and muscle quality in patients with chronic kidney disease: A retrospective observational study
Our study demonstrates that the newly developed SPPARMα significantly lowers TG levels in CKD patients without harming their kidneys. Additionally, only patients treated with SPPARMα showed improvement in muscle quality. These findings suggest that SPPARMα may be a valuable treatment option for CKD patients with dyslipidemia, particularly those with low muscle quality.
Authors
- Tomoaki Takata (ORCID: https://orcid.org/0000-0003-2959-6015)
- Yukari Mae (ORCID: https://orcid.org/0000-0002-8293-1620)
- Ken Kageyama (ORCID: https://orcid.org/0000-0002-0787-9789)
- Takuji Iyama
- Takaaki Sugihara (ORCID: https://orcid.org/0000-0003-0522-1884)
- Hajime Isomoto (ORCID: https://orcid.org/0000-0001-8858-6525)
- Hinako Hanada
- Yudai Fujino
- Sosuke Taniguchi
Institutions
- Tottori University (JP)
Publication Details
- Journal
- Clinical Nutrition ESPEN
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1016/j.clnesp.2024.11.029
- Citations
- 4
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- Japan Society for the Promotion of Science